Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence of Ruxolitinib XR Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

Next Previous
Trial Profile

Bioequivalence of Ruxolitinib XR Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Alopecia areata; Anaemia; Atopic dermatitis; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; COVID-19 pneumonia; Cytokine release syndrome; Discoid lupus erythematosus; Essential thrombocythaemia; Graft-versus-host disease; Haematological malignancies; Head and neck cancer; HER2 positive breast cancer; Hidradenitis suppurativa; HIV infections; Hodgkin's disease; Lichen planus; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prurigo nodularis; SARS-CoV-2 acute respiratory disease; Thalassaemia; Vitiligo; Vulvar lichen sclerosus
  • Focus Pharmacokinetics
  • Sponsors Incyte Corporation

Most Recent Events

  • 13 Feb 2025 Status changed from recruiting to completed.
  • 20 Sep 2024 Status changed from not yet recruiting to recruiting.
  • 21 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top